intermediateantipsychoticsmetabolic-monitoringstandard-of-careprescribing-responsibilityAANPCB
A PMHNP inherits a caseload from a departing provider and discovers that several patients on second-generation antipsychotics (SGAs) have not had metabolic monitoring for over a year. What is the most appropriate action?